Drammen

• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Ended recruitment
  2024-510716-71-00 5 2020-10-21 Multiple Sclerosis
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu … Ended recruitment
  2023-504624-25-00 4 2019-09-26 Advanced Non-Small Cell Lung Cancer
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• The TAF-MS study Ended
  2023-503814-62-00 4 2024-02-06 Multiple sclerosis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe … Ended
  2023-510317-26-00 4 2023-02-07 Amyotrophic Lateral Sclerosis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended
  2022-500363-12-00 4 2022-08-24 SARS CoV-2 (COVID-19)
• Efficacy and safety of UV1 vaccination +/- standard of care as first line treatment of patients with non-small cell lung cancer Ended
  2022-502437-25-00 4 2022-08-15 advanced or metastatic non-small cell lung cancer
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• PARASTOP - Paracetamol with Strong Opioids Ended
  2024-515012-53-00 5 2021-10-20 Metastatic cancer disease
• European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended
  2022-500385-99-00 5 2021-06-03 SARS-CoV II infection (Coronavirus disease)
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• First line treatment with osimertinib in non-small cell lung cancer, coupled with studies on biological samples. Ended
  2024-513881-20-00 4 2018-11-19 EGFR-mutated non-small cell lung cancer
• A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors Ended
  2023-503243-34-00 3 Solid tumor

Showing 49–63 of 63 trials